• Submitted by: Luis Manuel Mazorra
• Science and Technology
• 03 / 04 / 2012

---

Several developments in Congress will present Cuba Biotechnology Havana 2012, among them is the therapeutic vaccine against hepatitis B infection (Nasvac) that scored well in the last phase of clinical trials.
Biological Sciences Dr. Gerardo Guillén Nieto, vice president of the organizing committee, told reporters that the vaccine (nose) is unique because so far there is a similar one in the world to fight the disease.
He said research director of the Center for Biomedical Engineering and Biotechnology (ICGEB) that prepared for clinical research in Cuba and Bangladesh achieved a response than any other for the treatment of hepatitis B.
In the conference sessions will present the advances in clinical evaluations of other therapeutic vaccine against hepatitis C, developed on the Island
The event, to be held in Havana from 5 to 8 March, attended by over 600 experts from nearly 40 countries, including 350 Cubans. Participants highlighted and biologist Dr. Peter Agre, the United States, Nobel Prize in Chemistry 2003.
In opening the forum, Dr. Agre, a professor at Johns Hopkins, will give a lecture on the biochemistry and biotechnology and their implications for malaria.
As part of the conference there will be three symposia related to research and product development and cancer vaccines, dengue, AIDS and hepatitis B and C, among other ailments.
More than 70 foreign speakers and 30 Cubans will speak of the scientific institutions in Biotechnology 2012, on topics including the results of preclinical studies of a vaccine candidate against HIV / AIDS, the first phase of clinical trials is expected to begin this year, emphasized Guillén Nieto.
In 2011 the IGBC, for the second consecutive year, exported biotechnology products worth over $ 100 million to some 35 nations, said renowned scientist.
He stressed that the strength of Cuban biotechnology is the integration and ability to transfer technology to other countries Cuba.